AIM broadens patent portfolio with new Netherlands utility patent on Ampligen

AIM ImmunoTech announced that the Netherlands Patent Office has granted a utility patent covering rugged dsRNA, a double-stranded RNA product related to Ampligen, which claims cover, among other aspects, compositions and compositions for use in the prevention or treatment of COVID-19. The new patent broadens AIM‘s existing portfolio for COVID-19 treatments to include rugged dsRNA. Ampligen is AIM’s RNA product candidate designed to modulate the immune system. Data from in vitro, pre-clinical and clinical experiments strongly suggest that Ampligen has a broad-spectrum early-onset antiviral effect by stimulating a powerful innate immune response. The Company has conducted experiments in SARS-CoV-2 showing Ampligen has a powerful impact on viral replication.